Effect of unani medicine in the treatment of difficulty in speech after paralysis

An open labelled randomized clinical trial to evaluate the safety and efficacy of Dalak e lisan in post stroke aphasia - Nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/06/089672

Enrollment

Registered

2025-06-27

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R470- Dysphasia and aphasia

Interventions

Intervention1: dalak e lisan: SUFOOF FORM TO BE RUBBED ON TONGUE FOR 3-4 MINUTES UNTIL SALIVATION. 1.AQARQARHA (Anacyclus pyrethrum )-1gm 2.MAGHZ E BADAAM (Prunus amygdalus)-7 seeds 3.WAJ (Acorus cal

Eligibility

Inclusion criteria

Inclusion criteria: SEX Both sex STROKE of 6months Western aphasia battery wab 26

Exclusion criteria

Exclusion criteria: Other neurological conditions such as brain tumors dementia traumatic brain injury altered mental status dysarthria apraxia of speech Uncontrolled hypertension diabetes HbA1c 8 Pregnant and lactating women Unwillingness or inability to comply with the requirement of protocol Hearing and visual impairment

Design outcomes

Primary

Measure	Time frame
Western-aphasia-battery-wab score of greaterthan 26Timepoint: 30 days	—

Secondary

Measure	Time frame
NilTimepoint: Nil	—

Countries

India

Contacts

Public ContactDr SADATH UNNISA

Medical institute

ahmedfarhath66@gmail.com9848195067

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026